Tivozanib
![]() |
|
Names | |
---|---|
IUPAC name
1-{2-Chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methylisoxazol-3-yl)urea
|
|
Other names
AV-951
|
|
Identifiers | |
ChEMBL | ChEMBL1289494 |
ChemSpider | 8087481 |
6058 | |
Jmol 3D model | Interactive image |
PubChem | 9911830 |
UNII | 172030934T ![]() |
|
|
|
|
Properties | |
C22H19ClN4O5 | |
Molar mass | 454.87 g·mol−1 |
Vapor pressure | {{{value}}} |
Pharmacology | |
ATC code | L01 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor. It completed a trial investigation for the treatment of renal cell carcinomas.[1] The results did not result in FDA approval.
Mechanism
An oral quinoline urea derivative, tivozanib suppresses angiogenesis by being selectively inhibitory against vascular endothelial growth factor.[2] It was developed by AVEO Pharmaceuticals.[3] It is designed to inhibit all three VEGF receptors.[4]
Results
Phase III results on advanced renal cell carcinoma suggested a 30% or 3 months improvement in median PFS compared to sorafenib but showed an inferior overall survival rate of the experimental arm versus the control arm.[4][5] The Food and Drug Administration's Oncologic Drugs Advisory Committee voted in May 2013 13 to 1 against recommending approval of tivozanib for renal cell carcinoma. The committee felt the drug failed to show a favorable risk-benefit ratio and questioned the equipose of the trial design, which allowed control arm patients who used sorafenib to transition to tivozanib following progression disease but not those on the experimental arm using tivozanib to transition to sorafenib. The application was formally rejected by the FDA in June 2013, saying that approval would require additional clinical studies.[5]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
- ↑ A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma, clinicaltrials.gov
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Aveo Kidney Cancer Drug Shows Success; Shares Up, By John Kell, Dow Jones Newswires[dead link]
- ↑ 4.0 4.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 5.0 5.1 Lua error in package.lua at line 80: module 'strict' not found.
- Pages with reference errors
- Chemical articles without CAS Registry Number
- Articles without KEGG source
- Pages using collapsible list with both background and text-align in titlestyle
- Articles containing unverified chemical infoboxes
- Angiogenesis inhibitors
- Receptor tyrosine kinase inhibitors
- Quinolines
- Isoxazoles
- Experimental cancer drugs
- Antineoplastic and immunomodulating drug stubs
- Articles with dead external links from May 2011